Personalized medicine

What’s in it for rare diseases?

Sebastian Schee Genannt Halfmann, Laura Mählmann, Lada Leyens, Matthias Reumann, Angela Brand

    Research output: Chapter in Book/Report/Conference proceedingChapter

    1 Citation (Scopus)

    Abstract

    Personalised Medicine has become a reality over the last years. The emergence of ‘omics’ and big data has started revolutionizing healthcare. New ‘omics’ technologies lead to a better molecular characterization of diseases and a new understanding of the complexity of diseases. The approach of PM is already successfully applied in different healthcare areas such as oncology, cardiology, nutrition and for rare diseases. However, health systems across the EU are often still promoting the ‘one-size fits all’ approach, even if it is known that patients do greatly vary in their molecular characteristics and response to drugs and other interventions. To make use of the full potentials of PM in the next years ahead several challenges need to be addressed such as the integration of big data, patient empowerment, translation of basic to clinical research, bringing the innovation to the market and shaping sustainable healthcare systems.

    Original languageEnglish
    Title of host publicationAdvances in Experimental Medicine and Biology
    PublisherSpringer New York LLC
    Pages387-404
    Number of pages18
    DOIs
    Publication statusPublished - 01-01-2017

    Publication series

    NameAdvances in Experimental Medicine and Biology
    Volume1031
    ISSN (Print)0065-2598
    ISSN (Electronic)2214-8019

    Fingerprint

    Precision Medicine
    Rare Diseases
    Medicine
    Delivery of Health Care
    Cardiology
    Patient Participation
    Oncology
    Nutrition
    Innovation
    Health
    Technology
    Research
    Pharmaceutical Preparations
    Big data

    All Science Journal Classification (ASJC) codes

    • Biochemistry, Genetics and Molecular Biology(all)

    Cite this

    Schee Genannt Halfmann, S., Mählmann, L., Leyens, L., Reumann, M., & Brand, A. (2017). Personalized medicine: What’s in it for rare diseases? In Advances in Experimental Medicine and Biology (pp. 387-404). (Advances in Experimental Medicine and Biology; Vol. 1031). Springer New York LLC. https://doi.org/10.1007/978-3-319-67144-4_22
    Schee Genannt Halfmann, Sebastian ; Mählmann, Laura ; Leyens, Lada ; Reumann, Matthias ; Brand, Angela. / Personalized medicine : What’s in it for rare diseases?. Advances in Experimental Medicine and Biology. Springer New York LLC, 2017. pp. 387-404 (Advances in Experimental Medicine and Biology).
    @inbook{05b6792a6df44b2287cbc76d8c6954ca,
    title = "Personalized medicine: What’s in it for rare diseases?",
    abstract = "Personalised Medicine has become a reality over the last years. The emergence of ‘omics’ and big data has started revolutionizing healthcare. New ‘omics’ technologies lead to a better molecular characterization of diseases and a new understanding of the complexity of diseases. The approach of PM is already successfully applied in different healthcare areas such as oncology, cardiology, nutrition and for rare diseases. However, health systems across the EU are often still promoting the ‘one-size fits all’ approach, even if it is known that patients do greatly vary in their molecular characteristics and response to drugs and other interventions. To make use of the full potentials of PM in the next years ahead several challenges need to be addressed such as the integration of big data, patient empowerment, translation of basic to clinical research, bringing the innovation to the market and shaping sustainable healthcare systems.",
    author = "{Schee Genannt Halfmann}, Sebastian and Laura M{\"a}hlmann and Lada Leyens and Matthias Reumann and Angela Brand",
    year = "2017",
    month = "1",
    day = "1",
    doi = "10.1007/978-3-319-67144-4_22",
    language = "English",
    series = "Advances in Experimental Medicine and Biology",
    publisher = "Springer New York LLC",
    pages = "387--404",
    booktitle = "Advances in Experimental Medicine and Biology",

    }

    Schee Genannt Halfmann, S, Mählmann, L, Leyens, L, Reumann, M & Brand, A 2017, Personalized medicine: What’s in it for rare diseases? in Advances in Experimental Medicine and Biology. Advances in Experimental Medicine and Biology, vol. 1031, Springer New York LLC, pp. 387-404. https://doi.org/10.1007/978-3-319-67144-4_22

    Personalized medicine : What’s in it for rare diseases? / Schee Genannt Halfmann, Sebastian; Mählmann, Laura; Leyens, Lada; Reumann, Matthias; Brand, Angela.

    Advances in Experimental Medicine and Biology. Springer New York LLC, 2017. p. 387-404 (Advances in Experimental Medicine and Biology; Vol. 1031).

    Research output: Chapter in Book/Report/Conference proceedingChapter

    TY - CHAP

    T1 - Personalized medicine

    T2 - What’s in it for rare diseases?

    AU - Schee Genannt Halfmann, Sebastian

    AU - Mählmann, Laura

    AU - Leyens, Lada

    AU - Reumann, Matthias

    AU - Brand, Angela

    PY - 2017/1/1

    Y1 - 2017/1/1

    N2 - Personalised Medicine has become a reality over the last years. The emergence of ‘omics’ and big data has started revolutionizing healthcare. New ‘omics’ technologies lead to a better molecular characterization of diseases and a new understanding of the complexity of diseases. The approach of PM is already successfully applied in different healthcare areas such as oncology, cardiology, nutrition and for rare diseases. However, health systems across the EU are often still promoting the ‘one-size fits all’ approach, even if it is known that patients do greatly vary in their molecular characteristics and response to drugs and other interventions. To make use of the full potentials of PM in the next years ahead several challenges need to be addressed such as the integration of big data, patient empowerment, translation of basic to clinical research, bringing the innovation to the market and shaping sustainable healthcare systems.

    AB - Personalised Medicine has become a reality over the last years. The emergence of ‘omics’ and big data has started revolutionizing healthcare. New ‘omics’ technologies lead to a better molecular characterization of diseases and a new understanding of the complexity of diseases. The approach of PM is already successfully applied in different healthcare areas such as oncology, cardiology, nutrition and for rare diseases. However, health systems across the EU are often still promoting the ‘one-size fits all’ approach, even if it is known that patients do greatly vary in their molecular characteristics and response to drugs and other interventions. To make use of the full potentials of PM in the next years ahead several challenges need to be addressed such as the integration of big data, patient empowerment, translation of basic to clinical research, bringing the innovation to the market and shaping sustainable healthcare systems.

    UR - http://www.scopus.com/inward/record.url?scp=85037663316&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=85037663316&partnerID=8YFLogxK

    U2 - 10.1007/978-3-319-67144-4_22

    DO - 10.1007/978-3-319-67144-4_22

    M3 - Chapter

    T3 - Advances in Experimental Medicine and Biology

    SP - 387

    EP - 404

    BT - Advances in Experimental Medicine and Biology

    PB - Springer New York LLC

    ER -

    Schee Genannt Halfmann S, Mählmann L, Leyens L, Reumann M, Brand A. Personalized medicine: What’s in it for rare diseases? In Advances in Experimental Medicine and Biology. Springer New York LLC. 2017. p. 387-404. (Advances in Experimental Medicine and Biology). https://doi.org/10.1007/978-3-319-67144-4_22